問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Search Result

Search Result

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

葉智華

Recruiting

List

17Cases

2024-03-01 - 2028-06-30

Phase I/II

Active
A Phase 1b/2, Open-label Study of Amivantamab Monotherapy and Amivantamab in Addition to Standard of Care Therapeutic Agents in Participants with Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma

  • Condition/Disease

    Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma

  • Test Drug

    Amivantamab Paclitaxel Pembrolizumab Carboplatin

Participate Sites
5Sites

Recruiting5Sites

2025-01-01 - 2029-12-12

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
12Sites

Recruiting12Sites

2020-10-01 - 2021-01-17

Phase II

Not yet recruiting

  • Condition/Disease

  • Test Drug

Participate Sites
3Sites

Recruiting3Sites

2024-06-28 - 2028-03-31

Phase III

Active
A Phase 3 Open-label, Randomized Controlled Study to Evaluate the Efficacy and Safety of Petosemtamab Compared With Investigator's Choice Monotherapy Treatment in Previously Treated Patients With Incurable, Metastatic/Recurrent Head and Neck Squamous Cell Carcinoma

  • Condition/Disease

    Head and Neck Squamous Cell Carcinoma

  • Test Drug

    Intravenous infusion

Participate Sites
8Sites

Recruiting8Sites

2024-06-28 - 2028-05-31

Phase III

Active
A phase 3 randomized, open-label study to evaluate the efficacy and safety of petosemtamab plus pembrolizumab vs pembrolizumab in first-line treatment of recurrent or metastatic PD-L1+ head and neck squamous cell carcinoma

  • Condition/Disease

    Head and Neck Squamous Cell Carcinoma

  • Test Drug

    petosemtamab

Participate Sites
7Sites

Recruiting7Sites

2024-05-01 - 2028-12-31

Phase II/III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Recruiting5Sites

2022-08-31 - 2031-02-28

Phase III

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
9Sites

Recruiting9Sites

2024-01-01 - 2027-11-14

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
7Sites

Recruiting7Sites

2024-01-01 - 2027-07-31

Phase II

Completed
test

  • Condition/Disease

    test

  • Test Drug

    test

Participate Sites
6Sites

Recruiting6Sites

2023-04-01 - 2026-08-30

Phase I

Active
A First-in-Human, Open-label, Dose-escalation Trial With Expansion Cohorts to Evaluate Safety and Anti-tumor Activity of GEN1042 in Subjects With Malignant Solid Tumors

  • Condition/Disease

    Malignant Solid Tumors

  • Test Drug

    liquid

Participate Sites
7Sites

Recruiting7Sites

1 2
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB